206 related articles for article (PubMed ID: 24525285)
1. Neurotoxicity induced by antineoplastic proteasome inhibitors.
Alé A; Bruna J; Navarro X; Udina E
Neurotoxicology; 2014 Jul; 43():28-35. PubMed ID: 24525285
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
[TBL] [Abstract][Full Text] [Related]
3. [Management of proteasome inhibitor-induced peripheral neuropathy].
Takamatsu Y
Nihon Rinsho; 2015 Jan; 73(1):137-41. PubMed ID: 25626319
[TBL] [Abstract][Full Text] [Related]
4. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Martin TG
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect.
Kaplan GS; Torcun CC; Grune T; Ozer NK; Karademir B
Free Radic Biol Med; 2017 Feb; 103():1-13. PubMed ID: 27940347
[TBL] [Abstract][Full Text] [Related]
6. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced peripheral neurotoxicity: an update.
Argyriou AA; Cavaletti G; Bruna J; Kyritsis AP; Kalofonos HP
Arch Toxicol; 2014 Sep; 88(9):1669-79. PubMed ID: 25069804
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor-induced gastrointestinal toxicity.
Stansborough RL; Gibson RJ
Curr Opin Support Palliat Care; 2017 Jun; 11(2):133-137. PubMed ID: 28333868
[TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy in hematologic malignancies - Past, present and future.
Li T; Timmins HC; Lazarus HM; Park SB
Blood Rev; 2020 Sep; 43():100653. PubMed ID: 31983507
[TBL] [Abstract][Full Text] [Related]
10. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
[TBL] [Abstract][Full Text] [Related]
11. Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Yamamoto S; Egashira N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477371
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
Gilardini A; Marmiroli P; Cavaletti G
Curr Med Chem; 2008; 15(29):3025-35. PubMed ID: 19075650
[TBL] [Abstract][Full Text] [Related]
13. Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro.
Holzer AK; Suciu I; Karreman C; Goj T; Leist M
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409095
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
15. Old and new generation proteasome inhibitors in multiple myeloma.
Montefusco V; Mussetti A; Salas MQ; Martinelli G; Cerchione C
Panminerva Med; 2020 Dec; 62(4):193-206. PubMed ID: 32957744
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.
Argyriou AA; Bruna J; Marmiroli P; Cavaletti G
Crit Rev Oncol Hematol; 2012 Apr; 82(1):51-77. PubMed ID: 21908200
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the safety profile of proteasome inhibitors for treating various cancers.
Wang H; Guan F; Chen D; Dou QP; Yang H
Expert Opin Drug Saf; 2014 Aug; 13(8):1043-54. PubMed ID: 25005844
[TBL] [Abstract][Full Text] [Related]
18. Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.
Campo C; Da Silva Filho MI; Weinhold N; Goldschmidt H; Hemminki K; Merz M; Försti A
Neurochem Res; 2017 Mar; 42(3):925-931. PubMed ID: 27422265
[TBL] [Abstract][Full Text] [Related]
19. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Broyl A; Jongen JL; Sonneveld P
Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
[TBL] [Abstract][Full Text] [Related]
20. Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib.
Jannuzzi AT; Arslan S; Yilmaz AM; Sari G; Beklen H; Méndez L; Fedorova M; Arga KY; Karademir Yilmaz B; Alpertunga B
Redox Biol; 2020 May; 32():101502. PubMed ID: 32244176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
